Phase 3Completed

A Study of ABT-414 in Participants With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

A Randomized, Placebo Controlled Phase 3 Study of ABT-414 With Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance1)

Sponsor
AbbVie (Industry)
Enrollment
691 enrolled
Conditions
Glioblastoma; Gliosarcoma
Interventions
Temozolomide; Depatuxizumab mafodotin; Radiation; Placebo for ABT-414
Ages
adults, older adults
Registry
NCT02573324, EUCTR2015-001166-26

Full record on ClinicalTrials.gov

From the registry

This study seeks to determine whether the addition of ABT-414 to concomitant radiotherapy and temozolomide (TMZ) followed by combination of ABT-414 with adjuvant TMZ prolongs overall survival (OS) among participants with newly diagnosed glioblastoma (GBM) with epidermal growth factor receptor (EGFR) amplification. In addition, there is a Phase 1, open-label, multicenter sub-study to assess the pharmacokinetics, safety and tolerability of ABT-414 in participants with newly diagnosed EGFR-amplified GBM who have mild or moderate hepatic impairment.

Primary outcomes

  • Overall Survival (OS)

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Registered

  5. Started